Videos

Ramsey-Goldman discussed how the lupus field has shifted from her earlier career.

Assassi reflects on the FDA approval of nerandomilast for progressive pulmonary fibrosis and the clinical benefits of the new PDE4B-targeted treatment option.

ACR 2025 research shows polygenic risk scores correlate with specific SLE phenotypes, highlighting potential applications for clinical risk assessment.

At ACR 2025, Dapas discusses how polygenic risk scores link genetic risk to SLICC criteria, advancing precision medicine in systemic lupus erythematosus.

Mease discussed the latest updates on apremilast and growing attention to cardiometabolic outcomes at ACR Convergence 2025.

Mease discussed the latest updates on deucravacitinib and zasocitinib at ACR Convergence 2025.

Ramsey-Goldman emphasized the importance of QoL in lupus, looking beyond disease scores.

Ramsey-Goldman discussed the potential of NAC for treating systemic lupus erythematosus.

Khasru discussed the potential of adMSCs to improve outcomes in knee osteoarthritis.

At the SDPA Fall Conference, Singla speaks in an interview regarding screening patients with psoriasis for psoriatic arthritis (PsA).

Explore the complexities of psoriatic arthritis, its symptoms, and the importance of multidisciplinary management for effective treatment.

Cuda also discussed further research she'd like to do with cognition and SLE.

Conaghan discussed the potential of StEPP as a measure in clinical trials.

Cuda discussed the potential of the NIH toolbox to easily assess cognitive effects in clinical trials.

Conaghan discussed the potential of LEVI-04 for knee osteoarthritis at ACR 2025.

Cuda discussed the link between SLE disease activity and cognitive deficits,

Phase 2 trial shows ianalumab achieves sustained lupus disease control, supports steroid tapering, and increases time in remission over 1 year.

Phase 3 data show dapirolizumab pegol improved remission and disease stability in lupus; a second trial and patient-reported outcomes are now underway.

At ACR 2025, Vital discussed phase 3 data showing dapirolizumab pegol improved remission and stabilized disease activity in patients with lupus.

Jin discussed new evidence supporting the immune-modulating effects of low-dose IL-2 at ACR 2025.

Mease discussed the latest updates on bimekizumab, sonelokimab, and izokibep at ACR Convergence 2025.

Recent trial findings show Nanoencapsulated Sirolimus Plus Pegadricase can improve symptoms of uncontrolled gout.

Graf shared his excitement for a potential new first-in-class therapy for rheumatoid arthritis.

Obinutuzumab was approved earlier in October for LN under the name Gazyva.

Behrens discussed strong data supporting secukinumab's use over ustekinumab post-TNF inhibitor in PsA.

Daien shared her excitement for new data supporting fiber supplementation to improve MTX response in rheumatoid arthritis.

Conaghan discussed findings from the ENX-CL-05-001 phase 2a trial at the ACR Convergence.

Mysler emphasized the first definitive evidence informing sequencing after failing a first TNF inhibitor.

Prajapati discussed the impact of the expanded approval of guselkumab to pediatric PsO and psoriatic arthritis.

Kimura also highlighted the importance of coordinating with pediatricians.